Advaxis nabs SynCo Bio for manufacturing of its lead cancer immunotherapy

By Zachary Brennan

- Last updated on GMT

Advaxis nabs SynCo Bio for manufacturing of its lead cancer immunotherapy
Advaxis nabs SynCo Bio for manufacturing of its lead cancer immunotherapy
Biotech Advaxis has selected CMO SynCo Bio Partners B.V to manufacture Advaxis' potential cervical cancer immunotherapy.

Under the agreement, SynCo will assist Advaxis in developing scale-up and commercial manufacturing processes for ADXS-HPV bulk drug substance and drug product.

Advaxis plans to initiate registration trials​ by the end of this year with ADXS-HPV for the treatment of cervical cancer, and “we would expect the product is on the world market in the second half of 2017​,” Shawn Walsh, director of manufacturing at Advaxis, told BioPharma-Reporter.com

We were looking for a partner to help with commercialization and they have a track record of scaling up​,” he added. “From a fermentation standpoint, we still haven’t finalized plans, but we’re looking to use single-use​” bioreactors. SynCo has facilities in Amsterdam, Netherlands.

ADXS-HPV has demonstrated improved survival and objective tumor responses in a Phase 2 trial in 110 patients with recurrent cervical cancer. Advaxis is now planning the registrational program for ADXS-HPV.

The treatment is also being evaluated in other HPV-associated cancers including a Phase 2 in advanced cervical cancer, a Phase 1/2 in head and neck cancer, and a Phase 1/2 in anal cancer. ADXS-HPV has been granted orphan drug designation for both anal and head and neck cancers.

Pierre Warffemius, CEO of SynCo Bio Partners, added, "SynCo is very pleased to enter into a long-term manufacturing collaboration and looks forward to working with Advaxis to support global licensure of ADXS-HPV.

“Our leading position for supply of live microbial biopharmaceuticals, through providing high quality manufacturing services, will bring this therapeutic vaccine safely to patients for the treatment of HPV-associated cancers​."   

Related topics: Pipelines, Bio Developments, Bioreactors

Related news

Related products

show more

Manufacturing of hiPSC-Derived Cardiomyocytes

Manufacturing of hiPSC-Derived Cardiomyocytes

Eppendorf for Bioprocess – Solutions that grow with you | 29-Oct-2020 | Application Note

Effective drug discovery and development relies on the availability of predictive preclinical model systems. Technologies based on human induced pluripotent...

Follow us

Products

View more

Webinars